[HTML][HTML] Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
JD Hamilton, M Suárez-Farinas, N Dhingra… - Journal of Allergy and …, 2014 - Elsevier
Background Severe atopic dermatitis (AD) has a high unmet need for effective and safe
therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α,
markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the
molecular level has not been characterized. Objectives We sought to evaluate dupilumab
modulation of the AD molecular signature. Methods We performed transcriptomic analyses
of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to …
therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α,
markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the
molecular level has not been characterized. Objectives We sought to evaluate dupilumab
modulation of the AD molecular signature. Methods We performed transcriptomic analyses
of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to …
